人乳头瘤状甲状腺癌细胞TPC-1

细胞名称

人乳头瘤状甲状腺癌细胞TPC-1

货物编码

BFN680325

产品规格

T25培养瓶x1

1.5ml冻存管x2

细胞数量

1x10^6

1x10^6

保存温度

37℃

-198℃

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研   3类

培养体系

DMEM高糖（HYCLONE SH30022.01)+10%FBS+1%三抗

培养温度

37℃

二氧化碳浓度

5%

简介

人乳头瘤状甲状腺癌细胞TPC-1取自女性供体。

注释

Omics: Mitochondrial genome sequenced.

Omics: Transcriptome analysis.

基因突变

Gene fusion CCDC6-RET (RET/PTC1) (PubMed=7491517; PubMed=30737244).

Homozygous for CDKN2A p.Ala68fs (c.204_208delGGAGC) (PubMed=30737244).

Heterozygous for STAG2 p.Gln1089Ter (c.3265C>T) (PubMed=30737244).

Heterozygous for TERT c.1-124C>T (c.228C>T) (C228T); in promoter (PubMed=23833040; PubMed=30737244).

HLA信息

/

STR信息

Amelogenin X

CSF1PO 11,12

D3S1358 16,17

D5S818 8,10

D7S820 11

D8S1179 11,17

D13S317 11,12

D16S539 9

D18S51 13,16

D21S11 30,31.2

FGA 20,21

Penta D 9,13

Penta E 18

TH01 9

TPOX 11

vWA 14,18

参考文献

PubMed=22087789; DOI=10.1186/1755-8166-4-26

 Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.

 Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.

 Mol. Cytogenet. 4:26-26(2011)

PubMed=23162534; DOI=10.3389/fendo.2012.00133

 Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A., van Staveren W.C.G., Maenhaut C.

 Thyroid cancer cell lines: an overview.

 Front. Endocrinol. 3:133-133(2012)

PubMed=23833040; DOI=10.1210/jc.2013-2383

 Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.

 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

 J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953

 Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.

 Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.

 Clin. Cancer Res. 25:3141-3151(2019)